The U.S. Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA), Merck and Co., Inc.) for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL), or those who have relapsed after three or more prior lines of therapy. March 14, 2017. More Information: https://www.fda.gov/Drugs/
El Sentido De La Libertad - Filosofía & Co.
Hace 12 minutos